JP2022542430A5 - - Google Patents
Info
- Publication number
- JP2022542430A5 JP2022542430A5 JP2022506356A JP2022506356A JP2022542430A5 JP 2022542430 A5 JP2022542430 A5 JP 2022542430A5 JP 2022506356 A JP2022506356 A JP 2022506356A JP 2022506356 A JP2022506356 A JP 2022506356A JP 2022542430 A5 JP2022542430 A5 JP 2022542430A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- minutes
- cdr
- seq
- neonatal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093280A JP2025138661A (ja) | 2019-08-01 | 2025-06-04 | Ｆｃｒｎ抗体およびその使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881897P | 2019-08-01 | 2019-08-01 | |
| US62/881,897 | 2019-08-01 | ||
| PCT/US2020/044731 WO2021022249A1 (en) | 2019-08-01 | 2020-08-03 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093280A Division JP2025138661A (ja) | 2019-08-01 | 2025-06-04 | Ｆｃｒｎ抗体およびその使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542430A JP2022542430A (ja) | 2022-10-03 |
| JP2022542430A5 true JP2022542430A5 (https=) | 2023-08-14 |
Family
ID=74229292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506356A Pending JP2022542430A (ja) | 2019-08-01 | 2020-08-03 | Ｆｃｒｎ抗体およびその使用の方法 |
| JP2025093280A Pending JP2025138661A (ja) | 2019-08-01 | 2025-06-04 | Ｆｃｒｎ抗体およびその使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093280A Pending JP2025138661A (ja) | 2019-08-01 | 2025-06-04 | Ｆｃｒｎ抗体およびその使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220259308A1 (https=) |
| EP (1) | EP4007605A4 (https=) |
| JP (2) | JP2022542430A (https=) |
| CN (1) | CN114630678A (https=) |
| AU (1) | AU2020319897A1 (https=) |
| CA (1) | CA3148826A1 (https=) |
| MX (1) | MX2022001380A (https=) |
| WO (1) | WO2021022249A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| JP7755725B2 (ja) * | 2021-08-13 | 2025-10-16 | ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド | Ｆｃｒｎを特異的に認識する抗体およびその使用 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| AR131560A1 (es) * | 2023-01-06 | 2025-04-09 | argenx BV | Métodos para tratar pots mediante el uso de antagonistas de fcrn |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| CN119326887B (zh) * | 2024-10-20 | 2025-09-05 | 华中农业大学 | 动物FcRn蛋白在控制猪繁殖与呼吸综合征病毒感染性中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ251582A (en) * | 1992-04-01 | 1997-07-27 | Merck & Co Inc | Recombinant human anti-hiv antibodies, methods for their cloning and expression and pharmaceutical compositions thereof |
| DK2236154T3 (en) * | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| WO2009131702A2 (en) * | 2008-04-25 | 2009-10-29 | Dyax Corp. | Antibodies against fcrn and use thereof |
| AU2011328246B2 (en) * | 2010-11-08 | 2016-06-30 | Ablynx N.V. | CXCR2 binding polypeptides |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| RS64768B1 (sr) * | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| CN109641045A (zh) * | 2016-04-25 | 2019-04-16 | Synt免疫公司 | 人源化亲和力成熟的抗fcrn抗体 |
| SMT202400004T1 (it) * | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
| CN109952314A (zh) * | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| BR112020006692A2 (pt) * | 2017-10-04 | 2020-10-06 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa |
| CA3081144A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CN113518783A (zh) * | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| JP2023509195A (ja) * | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| AU2021292200A1 (en) * | 2020-06-17 | 2023-02-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
-
2020
- 2020-08-03 EP EP20846154.1A patent/EP4007605A4/en active Pending
- 2020-08-03 US US17/597,928 patent/US20220259308A1/en active Pending
- 2020-08-03 MX MX2022001380A patent/MX2022001380A/es unknown
- 2020-08-03 WO PCT/US2020/044731 patent/WO2021022249A1/en not_active Ceased
- 2020-08-03 AU AU2020319897A patent/AU2020319897A1/en active Pending
- 2020-08-03 CA CA3148826A patent/CA3148826A1/en active Pending
- 2020-08-03 CN CN202080069321.0A patent/CN114630678A/zh active Pending
- 2020-08-03 JP JP2022506356A patent/JP2022542430A/ja active Pending
-
2025
- 2025-06-04 JP JP2025093280A patent/JP2025138661A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542430A5 (https=) | ||
| KR100271333B1 (ko) | 다발성 경화증 치료용 씨디더블유(CDw) 52-특이 항체 | |
| Stangel et al. | Intravenous immunoglobulin treatment of neurological autoimmune diseases | |
| EP0663836B1 (en) | Treatment of autoimmune and inflammatory disorders | |
| JP2740640B2 (ja) | Ｌｅｕ３表現型Ｔ細胞媒介性自己免疫病の治療用組成物 | |
| JP2025138661A (ja) | Ｆｃｒｎ抗体およびその使用の方法 | |
| Ochs et al. | Safety and patient acceptability of intravenous immune globulin in 10% maltose | |
| US5660826A (en) | Therapeutic sepsis treatment using antagonists to PTHrP | |
| CN113660981A (zh) | 结节性痒疹患者的皮肤病变和瘙痒的治疗 | |
| RS54658B1 (sr) | Lečenje multiple skleroze (ms) sa kampat-1 h | |
| WO1991007986A1 (en) | Method of treating septic shock | |
| CN116507365A (zh) | 抗ox40抗体在治疗肿瘤或癌症中的应用 | |
| JP2023535792A (ja) | コロナウイルス治療のための抗ｃｄ３抗体 | |
| JP2005529152A5 (https=) | ||
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| EP1100829B1 (en) | Use of basiliximab in the treatment of rheumatoid arthritis or skin diseases | |
| JP2024505923A5 (https=) | ||
| Davis et al. | Neutralization of airway effects on bradykinin by antibodies | |
| Ramesh et al. | Therapeutic uses of intravenous immunoglobulin (IVIG) in children | |
| US20260042838A1 (en) | Methods and compositions for treating autoimmune hemolytic anemia (aiha) | |
| CA2060384C (en) | A pharmaceutical composition containing an antibody recognizing the cdw52 antigen | |
| WO2026096713A1 (en) | Treatment of warm autoimmune hemolytic anemia | |
| CA3224173A1 (en) | Method of administering anti-hpa-1a monoclonal antibody | |
| JP2022524814A5 (https=) | ||
| CN118021955A (zh) | 用于治疗il-17a介导的疾病或病症的方法和组合物 |